David J. Farrell - Concepedia

Author

David J. Farrell

Also Known As

D J Farrell, D. J. Farrell, D.J Farrell, D.J. FARRELL, D.J. Farrell, David Farrell, David J Farrell, David J. Farrell, David John Farrell, Farrell, David

340

Publications

11.3K

Citations

H-Index

147

Concepts

All Affiliations

JMI Laboratories Tufts University University of New England Micropore Technologies (United Kingdom)University of Toronto

About

David J. Farrell is an author at JMI Laboratories specializing in medicine, antimicrobial resistance, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	104	5K
2	Health Sciences	35	64	3K
3	Public Health	14	14	576
4	Education	11	11	602
5	Engineering	11	11	343

David J. Farrell

203

Publications

10.4K

Citations

H-Index

Page 1

	Year	Citations
The Effect of Telithromycin in Acute Exacerbations of Asthma Sebastian L. Johnston, Francesco Blasi, Peter Black, New England Journal of Medicine	2006	290
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012 Hélio S. Sader, David J. Farrell, Robert K. Flamm, International Journal of Antimicrobial Agents Gram-negative BacteriologyAntimicrobial SusceptibilityEuropean HospitalsAntimicrobial StewardshipAntibiotics	2014	253
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011) Hélio S. Sader, David J. Farrell, Robert K. Flamm, Diagnostic Microbiology and Infectious Disease Gram-negative BacteriologyAntimicrobial SusceptibilityEuropean HospitalsAntibioticsMedicine	2013	236
Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States David J. Farrell, Keith P. Klugman, Michael E. Pichichero The Pediatric Infectious Disease Journal	2007	223
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) David J. Farrell, Robert K. Flamm, Hélio S. Sader, Antimicrobial Agents and Chemotherapy	2013	202
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4 Stephen G. Jenkins, Steven D. Brown, David J. Farrell Annals of Clinical Microbiology and Antimicrobials	2008	169
Detection of a New <i>cfr</i> -Like Gene, <i>cfr</i> (B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program Lalitagauri M. Deshpande, Deborah Ashcraft, Heather P. Kahn, Antimicrobial Agents and Chemotherapy	2015	158
Novel Mechanism of Resistance to Oxazolidinones, Macrolides, and Chloramphenicol in Ribosomal Protein L4 of the Pneumococcus Nicole Wolter, Anthony M. Smith, David J. Farrell, Antimicrobial Agents and Chemotherapy	2005	155
Molecular characterization of macrolide resistance mechanisms among <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i> isolated from the PROTEKT 1999-2000 study David J. Farrell, Ian Morrissey, Sarah Bakker, Journal of Antimicrobial Chemotherapy	2002	155
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12) Hélio S. Sader, David J. Farrell, Mariana Castanheira, Journal of Antimicrobial Chemotherapy	2014	149

Page 1